Amneal Pharmaceuticals, Inc. Class A Common Stock (NASDAQ:AMRX) — Market Cap & Net Worth
Market Cap & Net Worth: Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)
Amneal Pharmaceuticals, Inc. Class A Common Stock (NASDAQ:AMRX) has a market capitalization of $5.92 Billion ($5.92 Billion) as of October 8, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3163 globally and #1113 in its home market, demonstrating a -2.72% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Amneal Pharmaceuticals, Inc. Class A Common Stock's stock price $19.65 by its total outstanding shares 348296027 (348.30 Million).
Amneal Pharmaceuticals, Inc. Class A Common Stock Market Cap History: 2025 to 2026
Amneal Pharmaceuticals, Inc. Class A Common Stock's market capitalization history from 2025 to 2026. Data shows growth from $4.39 Billion to $6.84 Billion (0.00% CAGR). Check current stock price of Amneal Pharmaceuticals, Inc. Class A Com for real-time trading data and today's change.
Amneal Pharmaceuticals, Inc. Class A Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Amneal Pharmaceuticals, Inc. Class A Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see AMRX operating cash flow for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
1.45x
Amneal Pharmaceuticals, Inc. Class A Common Stock's market cap is 1.45 times its annual revenue
Latest Price to Earnings (P/E) Ratio
60.90x
Amneal Pharmaceuticals, Inc. Class A Common Stock's market cap is 60.90 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $4.39 Billion | $3.02 Billion | $72.06 Million | 1.45x | 60.90x |
Competitor Companies of AMRX by Market Capitalization
Companies near Amneal Pharmaceuticals, Inc. Class A Common Stock in the global market cap rankings as of October 8, 2026. See Amneal Pharmaceuticals, Inc. Class A Com balance sheet independence to understand what proportion of total assets are financed by equity.
Key companies related to Amneal Pharmaceuticals, Inc. Class A Common Stock by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #524 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #599 globally with a market cap of $45.58 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #620 globally with a market cap of $44.06 Billion USD ( CN¥301.09 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #629 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #524 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #599 | GALDERMA GROUP AG | NYSE:GALDY | $45.58 Billion | $39.09 |
| #620 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.06 Billion | CN¥47.20 |
| #629 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €15.90 |
Amneal Pharmaceuticals, Inc. Class A Common Stock Historical Marketcap From 2025 to 2026
Between 2025 and today, Amneal Pharmaceuticals, Inc. Class A Common Stock's market cap moved from $4.39 Billion to $ 6.84 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $6.84 Billion | +55.95% |
| 2025 | $4.39 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 8th, 2026 the market cap of Amneal Pharmaceuticals, Inc. Class A Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.92 Billion USD |
| MoneyControl | $5.92 Billion USD |
| MarketWatch | $5.92 Billion USD |
| marketcap.company | $5.92 Billion USD |
| Reuters | $5.92 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms … Read more